Biotech · Public company · Boston, MA, US

Tango Therapeutics, Inc.

Ticker TNGX · SEC CIK 0001819133

Track this companyFree. Adds Tango Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials75 recruiting or active

Pipeline programs14From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline14

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPHASE1_PHASE2 · RECRUITING · started May 31, 2025ClinicalTrials.gov NCT06922591 · fetched Nov 12, 2026
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossPHASE1_PHASE2 · RECRUITING · started Mar 24, 2025ClinicalTrials.gov NCT06810544 · fetched Nov 12, 2026
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 29, 2024ClinicalTrials.gov NCT06188702 · fetched Nov 12, 2026
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsPHASE1_PHASE2 · TERMINATED · started Dec 8, 2023ClinicalTrials.gov NCT06065059 · fetched Nov 12, 2026
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 12, 2023ClinicalTrials.gov NCT05887492 · fetched Nov 12, 2026
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsPHASE1_PHASE2 · RECRUITING · started May 26, 2023ClinicalTrials.gov NCT05732831 · fetched Nov 12, 2026
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsPHASE1_PHASE2 · TERMINATED · started Mar 23, 2022ClinicalTrials.gov NCT05275478 · fetched Nov 12, 2026